Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Biomarkers, Genetic Risk, and the Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)

NCT06416267 is registered in ClinicalTrials.gov with University of Haifa as lead sponsor.

NCT NCT06416267
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06416267 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Biomarkers, Genetic Risk, and the Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)
Lead sponsor
University of Haifa
Phase
Observational
Overall status
Not yet recruiting
Start date
August 31, 2024
Completion date
December 31, 2040
Enrollment
1,500 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, autoimmune diseases, cancers, cardiovascular diseases, chronic lymphocytic leukemia, dementia, infections, monoclonal b-cell lymphocytosis, parkinson disease